Raw Material Data Poised to Reduce Biopharmaceutical Variability
This article was originally published in The Gold Sheet
Executive Summary
An initiative to increase the speed and extent of raw material data flow could enable biopharmaceutical companies to reduce the variability and increase the reliability of their manufacturing processes. Amgen shares successes with internal trending exercise and discusses proposed ASTM E55 data standard for use by the industry and its raw material suppliers.